Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA

28 Aug 2018

Abstract excerpt

Novel treatments for multiple myeloma (MM) have increased rates of complete response, raising interest in more accurate methods to evaluate residual disease. Cell-free tumor DNA (cfDNA) analysis may represent a minimally invasive approach complementary to multiparameter flow cytometry (MFC) and molecular methods on bone marrow aspirates. A sequencing approach using the Ion Torrent Personal Genome Machine was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30165206
DOI: 10.1016/j.jmoldx.2018.07.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNAPMID 30165206Read ↗

Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple MyelomaSemantic proximity Read ↗

Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cellsSemantic proximity Read ↗

Tracking myeloma tumor DNA in peripheral blood.Semantic proximity Read ↗

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myelomaSemantic proximity Read ↗

Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.Semantic proximity Read ↗

High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosisSemantic proximity Read ↗

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.Semantic proximity Read ↗

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.Semantic proximity Read ↗

Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple MyelomaSemantic proximity Read ↗

Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myelomaSemantic proximity Read ↗

Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.Semantic proximity Read ↗

MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma PathologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.